News

AbstractTransthyretin (TTR) amyloidosis manifests in two distinct forms: hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt). Despite being one of…

For many living with ATTR-CM amyloidosis, recent advances have brought hope. In just seven years we have gone from no approved treatments to having a number of…

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or…

AbstractCardiac amyloidosis is a fatal disorder caused by deposition of abnormally folded protein in the interstitial space. One of the proteins most associated…

Variant transthyretin (ATTRv) amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to amyloid fibril deposition. The Balearic…

AbstractThe accumulation of amyloid fibrils has been identified in tissues outside the brain, yet little is understood about the formation of extracerebral…

Sabrina Rebello, ARC’s Senior Research Manager, presented an in-depth overview of key insights from our Annual Community Survey. This webinar focused on…

July 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a…

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and…

AbstractBackgroundThe diagnosis of cardiac amyloidosis can be achieved noninvasively for transthyretin amyloid cardiomyopathy through nuclear scintigraphy with bone…